Kronox Lab Sciences IPO
Kronox Lab Sciences IPO — date, price band, lot size & details 2024
Kronox Lab Sciences listed on 10 Jun 2024 at ₹164.95, 21.3% above the ₹136 issue price.
Kronox Lab Sciences makes high purity speciality fine chemicals used in APIs, formulations, research, nutraceuticals, biotech and other industries. Its total income was Rs 97.50 crore in FY2023.
Stock price
Kronox Lab Sciences is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 14 November.
- Open 03 Jun 2024
- Close 05 Jun 2024
- Allotment 06 Jun 2024
- Refund/credit 07 Jun 2024
- Listing 10 Jun 2024
Issue summary
The terms of the offer, as filed.
| IPO Dates | 3 to 5 Jun, 2024 |
|---|---|
| Price Band | ₹129 – ₹136 |
| Face Value | ₹10 |
| Lot Size | 110 Shares |
| Issue Size | ₹130.15 Cr |
| Sale Type | OFS only |
| Listing On | BSE, NSE |
| Registrar | KFin Technologies Limited |
| Min Investment | ₹ 14,960 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 110 shares at the ₹136 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 110 | ₹14,960 |
| Retail (max) | 13 | 1,430 | ₹1,94,480 |
| S-HNI (min) | 14 | 1,540 | ₹2,09,440 |
| S-HNI (max) | 66 | 7,260 | ₹9,87,360 |
| B-HNI (min) | 67 | 7,370 | ₹10,02,320 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Profit after tax rose from Rs 9.73 crore in FY2021 to Rs 16.62 crore in FY2023.
- 02The source puts the PAT margin at 22.60% and return on net worth at 25.66%.
- 03Borrowing was negligible, at Rs 0.64 crore on 31 March 2022.
- 04Profit after tax was Rs 15.47 crore in the nine months to 31 December 2023.
- 05It sells more than 185 products to customers in over 20 countries.
Risks · 5
- 01The whole Rs 130.15 crore issue was offer for sale by the promoters, so no money went to the company.
- 02The pre-issue P/E was 30.37 at the upper band of Rs 136, based on EPS of Rs 4.48.
- 03The company is small, with total income of Rs 97.50 crore in FY2023.
- 04Its customers are in regulated sectors such as pharma, so quality failures would be costly. Net worth was Rs 60.28 crore.
- 05Promoters held 100% before the issue and 74.21% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Kronox Lab Sciences offer document.
| Metric | 31 Dec 2023 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Assets | 66.96 | 54.03 | 56.79 | 37.65 |
| Total Income | 68.44 | 97.50 | 83.34 | 63.24 |
| Profit After Tax | 15.47 | 16.62 | 13.63 | 9.73 |
| NET Worth | 60.28 | 44.68 | 40.35 | 26.81 |
| Reserves and Surplus | 15.56 | 7.58 | 40.11 | 26.57 |
| Total Borrowing | 0.64 | 0.01 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Kronox Lab Sciences RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Kronox Lab Sciences IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Pre-Issue | Post-Issue |
|---|---|---|
| EPS (₹) | ₹4.48 | ₹5.56 |
| P/E Ratio (x) | 30.37 | 24.47 |
| Market Cap at Offer Price (₹ Cr) | ₹469.63 | ₹378.40 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹136 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
How the company intends to use the proceeds of the issue.
Information about the usage of proceeds from the Kronox Lab Sciences IPO will be updated shortly.
Kronox Lab Sciences IPO Anchor Investors
6 anchor investors across 3 fund houses committed ₹39.04 Cr a day before the issue opened.
| Anchor Investor | Fund House | Shares | Amount (₹ Cr) | % of Anchor Book |
|---|---|---|---|---|
| Negen Undiscovered Value Fund | Negen | 557,260 | 7.58 | 19.41% |
| Chanakya Opportunities Fund I | Chanakya | 550,330 | 7.48 | 19.17% |
| Minerva Emerging Opportunities Fund Limited | - | 550,330 | 7.48 | 19.17% |
| Capri Global Capital Limited | - | 404,360 | 5.50 | 14.08% |
| Moneywise Financial Services Private Limited | - | 404,360 | 5.50 | 14.08% |
| Vpk Global Ventures Fund-Vpk Global Ventures Fund-Scheme I | - | 404,360 | 5.50 | 14.08% |
| Total anchor allocation | 39.04 | |||
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
Its products are used in making APIs, pharmaceutical formulations, scientific research, nutraceuticals, biotech applications, agrochemical formulations, personal care products, metal refineries and animal health.
It offers more than 185 products across the phosphate, sulphate, acetate, chloride, citrate and other families, and supplies customers in India and more than 20 countries.
The IPO was Rs 130.15 crore and was entirely an offer for sale by the three promoters, so the company received none of the money.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Kronox Lab Sciences IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Pantomath Capital Advisors Pvt Ltd
20 issues handledBest listing: Astron Paper & Board Mill (+130.0%). Weakest: Glottis (-34.9%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Kronox Lab Sciences?
The current Grey Market Premium is ₹36, or 26% over the issue price.
What is the Kronox Lab Sciences IPO price band?
₹129 to ₹136, on a face value of ₹10.
When is the allotment?
The basis of allotment is 6 June 2024, with listing on 10 June 2024.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — KFin Technologies Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
